(Q24202564)

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Randomised trial of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

The effect of oral and intravenous methylprednisolone treatment on subsequent relapse rate in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

A short-term randomized MRI study of high-dose oral vs intravenous methylprednisolone in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

The bioavailability of IV methylprednisolone and oral prednisone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

A randomized, controlled trial of oral high-dose methylprednisolone in acute optic neuritis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Corticosteroids or ACTH for acute exacerbations in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Mechanisms of glucocorticoid receptor action in noninflammatory and inflammatory cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Cost of managing an episode of relapse in multiple sclerosis in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Mechanisms of glucocorticoids in the control of neuroinflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

The effect of oral corticosteroid dosage on CT enhancing multiple sclerosis plaques.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Oral versus Intravenous Steroids for Treatment of Relapses in Multiple Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

Defining the response to interferon-β in relapsing-remitting multiple sclerosis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

USE OF AN ORAL CORTICOSTEROID IN THE TREATMENT OF MULTIPLE SCLEROSIS; A DOUBLE-BLIND STUDY

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021

Glucocorticosteroid therapy for multiple sclerosis: a critical review

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021

Comparison of the effects of oral versus intravenous methylprednisolone regimens on peripheral blood T lymphocyte adhesion molecule expression, T cell subsets distribution and TNF alpha concentrations in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021

Cost analysis of methylprednisolone treatment of multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021

Immunological effects of oral high-dose methylprednisolone in acute optic neuritis and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021

Double-blind randomized trial of ACTH versus dexamethasone versus methylprednisolone in multiple sclerosis bouts. Clinical, cerebrospinal fluid and neurophysiological results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021

Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021

Gastric tolerance of high-dose pulse oral prednisone in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006921.PUB3

7 January 2021